Welcome to our dedicated page for Syneos Health news (Ticker: SYNH), a resource for investors and traders seeking the latest updates and insights on Syneos Health stock.
Syneos Health, Inc. (Nasdaq: SYNH) is a prominent player in the biopharmaceutical solutions industry, offering comprehensive end-to-end clinical and commercial services. With a mission to shorten the distance from lab to life, the company is dedicated to accelerating the success of its clients in the biopharmaceutical sector.
Formed from the merger of INC Research and inVentiv Health, Syneos Health stands out as the only fully integrated biopharmaceutical solutions organization. The company leverages its extensive expertise and data insights to navigate the complexities of today's marketplace, providing smarter and faster solutions to its clients. Its services range from clinical trials to commercialization, ensuring that therapies reach patients efficiently.
Headquartered in Morrisville, N.C., Syneos Health operates in more than 110 countries, employing a talented team of professionals who deeply understand patient and physician behaviors as well as market dynamics. The company is committed to fostering a diverse, equitable, and inclusive culture, focusing on the well-being of its colleagues, customers, patients, communities, and the environment.
One of Syneos Health's recent significant achievements includes an agreement to go private through an acquisition by a consortium of private investment firms, which includes Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital. This transaction, approved by the company's stockholders, is expected to bolster Syneos Health's growth priorities and enhance its ability to deliver integrated solutions to its clients.
Among its current projects, Syneos Health has been enhancing its patient recruitment capabilities through a collaboration with Oracle Cerner LHN to address unmet needs in clinical trial enrollment and diversity. Furthermore, the company continues to invest in technology and data solutions to optimize clinical development and performance for its customers.
Financially, Syneos Health operates on solid footing, with ongoing support from its new private investors poised to further accelerate its transformation and fuel investments in technology. The company's commitment to innovation and customer success positions it as a leading force in the biopharmaceutical industry.
To stay updated on Syneos Health's latest developments, including their quarterly reports and strategic initiatives, visit syneoshealth.com and subscribe to their podcast.
Syneos Health (Nasdaq:SYNH) will announce its third quarter 2020 financial results on October 29, 2020, before the earnings call at 8:00 a.m. ET. The call will be accessible via webcast on the company's Investor Relations website or by phone using the designated numbers. An audio replay will be available for a week post-call. Syneos Health is a fully integrated biopharmaceutical solutions organization with a global reach, combining clinical and commercial expertise to expedite the delivery of therapies to patients.
Syneos Health (Nasdaq: SYNH) announced a secondary offering of 7,000,000 shares at $59.75 per share, with an expected close on September 17, 2020. The sale is led by affiliates of Thomas H. Lee Partners and Advent International, with Syneos not receiving any proceeds from the offering. The company also agreed to repurchase approximately $30 million worth of its shares from the underwriters at the same share price. Goldman Sachs & Co. LLC and Morgan Stanley are the underwriters for this offering.
On September 15, 2020, Syneos Health (SYNH) announced a secondary offering of 7,000,000 shares of its common stock by affiliates of Thomas H. Lee Partners and Advent International. The company will not sell any shares or receive proceeds from this offering. It has agreed to repurchase approximately $30 million of the shares from the underwriters at the offering price. Goldman Sachs and Morgan Stanley are the underwriters for the transaction. Investors are encouraged to review the registration statements and prospectus available on the SEC website for further information.
MORRISVILLE, N.C., Sept. 9, 2020 – Syneos Health (Nasdaq: SYNH) announced a rescheduling of its presentation at the Baird 2020 Global Healthcare Conference due to technical glitches. CEO Alistair Macdonald and CFO Jason Meggs will present today at 12:15 p.m. ET. A live webcast and presentation materials will be available on the Company’s Investor Relations website, enhancing accessibility for stakeholders.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a CRO and CCO, dedicated to improving customer performance globally.
Syneos Health (Nasdaq: SYNH) announced that CEO Alistair Macdonald and CFO Jason Meggs will present at the Baird 2020 Global Healthcare Conference on September 9, 2020, at 8:30 a.m. ET. A live webcast of the event, along with presentation materials and an archived audio replay, will be accessible on the Company's Investor Relations website.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO), serving over 110 countries with approximately 24,000 professionals.
Syneos Health (SYNH) reported a GAAP revenue of $1,013.4 million for Q2 2020, down 13.1% year-over-year. Net new business awards totaled $1,360.9 million, resulting in a book-to-bill ratio of 1.34x. The Clinical Solutions segment saw a revenue decline of 12.1% to $747.2 million, while Commercial Solutions dropped 16.0% to $266.2 million. Despite challenges from COVID-19, the company issued full-year guidance of $4,470 million to $4,570 million in revenue, along with adjusted EBITDA expectations of $600 million to $640 million.
Syneos Health (Nasdaq: SYNH) has signed a new three-year agreement with Pfizer to provide global product development solutions. This partnership strengthens their existing relationship, with a provision for Pfizer to extend the agreement by two additional years. Financial details are undisclosed. The collaboration will leverage Syneos Health's therapeutic expertise to optimize Pfizer's portfolio, ensuring efficient product development and trial processes.
Syneos Health (Nasdaq: SYNH) will announce its second quarter 2020 financial results on August 6, 2020, before an earnings call at 8:00 a.m. ET. The call can be accessed via webcast on the company's website or by telephone. Syneos Health, a fully integrated biopharmaceutical solutions organization, aims to enhance customer performance in over 110 countries, utilizing advanced technologies and insights to expedite crucial therapies to patients. A replay of the call will be available shortly after, along with audio access for a week.
MORRISVILLE, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq: SYNH) announced that CEO Alistair Macdonald and CFO Jason Meggs will present at two investor conferences. The events are the Jefferies Virtual Healthcare Conference on June 3, 2020, at 9:30 a.m. ET, and the William Blair 40th Annual Growth Stock Conference on June 9, 2020, at 9:00 a.m. ET. Live webcasts and presentation materials will be available on the Company’s Investor Relations website.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a CRO and CCO.
FAQ
What is the market cap of Syneos Health (SYNH)?
What is Syneos Health, Inc.?
What recent achievement did Syneos Health announce?
What services does Syneos Health offer?
What is the significance of Syneos Health's collaboration with Oracle Cerner LHN?
How many countries does Syneos Health operate in?
What is Syneos Health's commitment to diversity and inclusion?
What is Syneos Health's financial condition?
Where can I find more information about Syneos Health's latest developments?
What is the main goal of Syneos Health?
Who are the private investment firms involved in the acquisition of Syneos Health?
